SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+1.96%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$479M
AUM Growth
+$479M
(+7%)
Cap. Flow
+$61M
Cap. Flow
% of AUM
12.75%
Top 10 Holdings %
Top 10 Hldgs %
50.4%
Holding
82
New
23
Increased
27
Reduced
15
Closed
14
Top Buys
| 1 |
KalVista Pharmaceuticals
KALV
|
$12.5M |
| 2 |
Soleno Therapeutics
SLNO
|
$11.9M |
| 3 |
89bio
ETNB
|
$10.3M |
| 4 |
Neurocrine Biosciences
NBIX
|
$8.03M |
| 5 |
Disc Medicine
IRON
|
$6.26M |
Top Sells
| 1 |
Pliant Therapeutics
PLRX
|
$17.3M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$15M |
| 3 |
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
|
$9.72M |
| 4 |
Scholar Rock
SRRK
|
$7.92M |
| 5 |
Cogent Biosciences
COGT
|
$7.18M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
Verona Pharma
VRNA
$9.16B
| $34.7M | 7.09% | 545,872 +29,858 | +6% | +$1.9M |
|
2
Merus
MRUS
$4.98B
| $34.1M | 6.98% | 811,021 +130,176 | +19% | +$5.48M |
|
3
Nuvalent
NUVL
$5.52B
| $31.1M | 6.37% | 439,018 +39,004 | +10% | +$2.77M |
|
4
Akero Therapeutics
AKRO
$3.74B
| $29.1M | 5.96% | 719,992 -19,571 | -3% | -$792K |
|
5
Insmed
INSM
$28.8B
| $24.5M | 5.01% | 321,366 -50,864 | -14% | -$3.88M |
|
|
6
KalVista Pharmaceuticals
KALV
$678M
| $19.6M | 4.01% | 1,698,984 +1,086,811 | +178% | +$12.5M |
|
7
Veracyte
VCYT
$2.39B
| $18.8M | 3.84% | 633,832 +130,551 | +26% | +$3.87M |
|
8
Rhythm Pharmaceuticals
RYTM
$6.85B
| $17.9M | 3.66% | 337,605 +63,709 | +23% | +$3.37M |
|
9
Syndax Pharmaceuticals
SNDX
$1.41B
| $16.1M | 3.29% | 1,309,224 +78,824 | +6% | +$968K |
|
10
UroGen Pharma
URGN
$900M
| $15.3M | 3.12% | 1,381,158 +260,685 | +23% | +$2.88M |
|
11
Avidity Biosciences
RNA
$5.99B
| $12.1M | 2.48% | 411,312 -132,339 | -24% | -$3.91M |
|
|
12
Soleno Therapeutics
SLNO
$3.6B
| $11.9M | 2.43% | +166,417 | New | +$11.9M |
|
13
Ascendis Pharma
ASND
$11.8B
| $11.8M | 2.41% | 75,751 +24,260 | +47% | +$3.78M |
|
|
14
Disc Medicine
IRON
$2.07B
| $11.7M | 2.4% | 236,471 +126,090 | +114% | +$6.26M |
|
15
Oric Pharmaceuticals
ORIC
$994M
| $11.5M | 2.35% | 2,060,240 +881,940 | +75% | +$4.92M |
|
|
16
89bio
ETNB
$1.34B
| $11M | 2.25% | 1,510,498 +1,413,987 | +1,465% | +$10.3M |
|
17
Erasca
ERAS
$445M
| $10.1M | 2.06% | 7,367,996 -175,905 | -2% | -$241K |
|
18
Wave Life Sciences
WVE
$1.53B
| $8.49M | 1.74% | 1,050,374 +441,477 | +73% | +$3.57M |
|
|
19
Neurocrine Biosciences
NBIX
$13.8B
| $8.03M | 1.64% | +72,583 | New | +$8.03M |
|
20
Travere Therapeutics
TVTX
$1.56B
| $7.33M | 1.5% | 408,849 +131,484 | +47% | +$2.36M |
|
21
Gossamer Bio
GOSS
$562M
| $6.95M | 1.42% | 6,320,684 +148,837 | +2% | +$164K |
|
22
Gilead Sciences
GILD
$140B
| $6.95M | 1.42% | 62,029 +52,029 | +520% | +$5.83M |
|
|
BBOT
23
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $6.93M | 1.42% | 613,393 +100,024 | +19% | +$1.13M |
|
24
Elutia
ELUT
$96.7M
| $6.76M | 1.38% | 2,670,056 +887,785 | +50% | +$2.25M |
|
25
Praxis Precision Medicines
PRAX
$958M
| $6.29M | 1.29% | 166,074 +93,558 | +129% | +$3.54M |
|